Percentage of Participants With Response Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal) [clinicaltrials_resource:e6c2d5946f8f37bd570fda38d2dfb40b]
Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin >=11 gram (g) per deciliter (dl), platelets >=100*10^9 liter (l), neutrophils >=1.0*10^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by >=50% over pre-treatment but still >=5%.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Percentage of Participants With Response Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal) [clinicaltrials_resource:e6c2d5946f8f37bd570fda38d2dfb40b]
Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin >=11 gram (g) per deciliter (dl), platelets >=100*10^9 liter (l), neutrophils >=1.0*10^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by >=50% over pre-treatment but still >=5%.
Bio2RDF identifier
e6c2d5946f8f37bd570fda38d2dfb40b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e6c2d5946f8f37bd570fda38d2dfb40b
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants With Response
time frame [clinicaltrials_vocabulary:time-frame]
Day 1 of Cycle 2, 4, 6, 8; eac ...... r Cycle 8 or early withdrawal)
description
Percentage of participants wit ...... pre-treatment but still >=5%.
identifier
clinicaltrials_resource:e6c2d5946f8f37bd570fda38d2dfb40b
title
Percentage of Participants Wit ...... r Cycle 8 or early withdrawal)
@en
type
label
Percentage of Participants Wit ...... 2d5946f8f37bd570fda38d2dfb40b]
@en